Thromb Res
-
Publication Venue For
- Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.. 182:159-166. 2019
- Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey.. 180:25-27. 2019
- The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases.. 179:11-14. 2019
- Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis.. 171:1-6. 2018
- International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs.. 166:63-70. 2018
- Variants in chondroitin sulfate metabolism genes in thrombotic storm.. 161:43-51. 2018
- PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses.. 159:39-47. 2017
- Management of hereditary antithrombin deficiency in pregnancy.. 157:41-45. 2017
- Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial.. 156:184-190. 2017
- Generation and characterization of aptamers targeting factor XIa.. 156:134-141. 2017
- Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.. 146:113-118. 2016
- Recognizing the risk of postpartum thrombosis among obese women and planning accordingly.. 145:157-158. 2016
- Inter-observer reliability of the HERDOO2 clinical decision rule.. 141:136-138. 2016
- Systematic review of anticoagulant treatment of catheter-related thrombosis.. 136:1103-1109. 2015
- Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.. 135:659-665. 2015
- Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.. 135:50-57. 2015
- Characterization of antithrombin levels in pregnancy.. 134:648-651. 2014
- A mouse bleeding model to study oral anticoagulants.. 133 Suppl 1:S6-S8. 2014
- Hemostasis: old system, new players, new directions.. 133 Suppl 1:S1-S2. 2014
- Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.. 133:629-633. 2014
- In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.. 132:106-111. 2013
- Hemostatic properties of the FVIIa analog NN1731.. 129 Suppl 2:S49-S50. 2012
- Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy.. 129:e36-e40. 2012
- Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.. 129:1-2. 2012
- Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism.. 128:536-540. 2011
- Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin.. 127:576-581. 2011
- Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy.. 126:113-118. 2010
- Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.. 125:432-437. 2010
- Platelet binding and activity of recombinant factor VIIa.. 125 Suppl 1:S16-S18. 2010
- Wound healing in hemophilia B mice and low tissue factor mice.. 125 Suppl 1:S74-S77. 2010
- Diagnosis and management of inherited von Willebrand disease in the next decade: panel discussion.. 124 Suppl 1:S20-S21. 2009
- Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.. 117:439-446. 2006
- Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. 2017